Growth hormone secretagogue receptor antagonists as potential therapeutic agents for obesity.
- Published in:
- Drug Development Research, 2005, v. 65, n. 2, p. 50, doi. 10.1002/ddr.20011
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2005 AND VI 65 AND IP 2
Results: 5
1
2
Development of colon‐targeted albendazole‐β‐cyclodextrin‐complex drug delivery systems.
- Published in:
- Drug Development Research, 2005, v. 65, n. 2, p. 76, doi. 10.1002/ddr.20010
- By:
- Publication type:
- Article
3
Are p53 inhibitors potentially useful therapeutics?
- Published in:
- Drug Development Research, 2005, v. 65, n. 2, p. 43, doi. 10.1002/ddr.20009
- By:
- Publication type:
- Article
4
A quantitative approach to probe the dependence and correlation of food‐effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate‐release formulations.
- Published in:
- Drug Development Research, 2005, v. 65, n. 2, p. 55, doi. 10.1002/ddr.20008
- By:
- Publication type:
- Article
5
Inhibition of cell cycle and induction of apoptosis by 2‐oxoheksyl isothiocyanate and alyssin in cell lines carrying various inherited BRCA1 mutations.
- Published in:
- Drug Development Research, 2005, v. 65, n. 2, p. 84, doi. 10.1002/ddr.20007
- By:
- Publication type:
- Article